Your browser doesn't support javascript.
Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia.
Lynch, Sean A; Subbarao, Kanta; Mahanty, Siddhartha; Barber, Bridget E; Roulis, Eileen V; van der Hoek, Lia; McCarthy, James S; Spann, Kirsten M.
  • Lynch SA; QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
  • Subbarao K; WHO Collaborating Centre for Reference and Research on Influenza, Department of Microbiology and Immunology, Melbourne, VIC 3000, Australia.
  • Mahanty S; The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
  • Barber BE; The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
  • Roulis EV; QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
  • van der Hoek L; Australian Red Cross Lifeblood, Kelvin Grove, QLD 4059, Australia.
  • McCarthy JS; Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Institute for Infection & Immunity, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Spann KM; QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Viruses ; 13(8)2021 08 16.
Article in English | MEDLINE | ID: covidwho-1360822
ABSTRACT
The COVID-19 pandemic has highlighted the importance of understanding the immune response to seasonal human coronavirus (HCoV) infections such as HCoV-NL63, how existing neutralising antibodies to HCoV may modulate responses to SARS-CoV-2 infection, and the utility of seasonal HCoV as human challenge models. Therefore, in this study we quantified HCoV-NL63 neutralising antibody titres in a healthy adult population using plasma from 100 blood donors in Australia. A microneutralisation assay was performed with plasma diluted from 110 to 1160 and tested with the HCoV-NL63 Amsterdam-1 strain. Neutralising antibodies were detected in 71% of the plasma samples, with a median geometric mean titre of 14. This titre was similar to those reported in convalescent sera taken from individuals 3-7 months following asymptomatic SARS-CoV-2 infection, and 2-3 years post-infection from symptomatic SARS-CoV-1 patients. HCoV-NL63 neutralising antibody titres decreased with increasing age (R2 = 0.042, p = 0.038), but did not differ by sex. Overall, this study demonstrates that neutralising antibody to HCoV-NL63 is detectable in approximately 71% of the healthy adult population of Australia. Similar titres did not impede the use of another seasonal human coronavirus (HCoV-229E) in a human challenge model, thus, HCoV-NL63 may be useful as a human challenge model for more pathogenic coronaviruses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus Infections / Antibodies, Neutralizing / Coronavirus NL63, Human / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Oceania Language: English Year: 2021 Document Type: Article Affiliation country: V13081618

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus Infections / Antibodies, Neutralizing / Coronavirus NL63, Human / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Oceania Language: English Year: 2021 Document Type: Article Affiliation country: V13081618